131 related articles for article (PubMed ID: 25244069)
1. Assessing abuse potential of new analgesic medications following market release: an evaluation of Internet discussion of tapentadol abuse.
McNaughton EC; Black RA; Weber SE; Butler SF
Pain Med; 2015 Jan; 16(1):131-40. PubMed ID: 25244069
[TBL] [Abstract][Full Text] [Related]
2. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment.
Butler SF; McNaughton EC; Black RA
Pain Med; 2015 Jan; 16(1):119-30. PubMed ID: 25243972
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
[TBL] [Abstract][Full Text] [Related]
4. Measuring online endorsement of prescription opioids abuse: an integrative methodology.
McNaughton EC; Black RA; Zulueta MG; Budman SH; Butler SF
Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1081-92. PubMed ID: 22777908
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the abuse of tapentadol immediate release: the first 24 months.
Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH
J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317
[TBL] [Abstract][Full Text] [Related]
6. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
Butler SF; Oyedele NK; Dailey Govoni T; Green JL
JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.
Cepeda MS; Fife D; Ma Q; Ryan PB
J Pain; 2013 Oct; 14(10):1227-41. PubMed ID: 23850177
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.
Vosburg SK; Severtson SG; Dart RC; Cicero TJ; Kurtz SP; Parrino MW; Green JL
J Pain; 2018 Apr; 19(4):439-453. PubMed ID: 29224919
[TBL] [Abstract][Full Text] [Related]
9. Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders.
Severtson SG; Gurrola MC; Parrino MW; Ellis MS; Cicero TJ; Iwanicki JL; Dart RC
J Opioid Manag; 2023; 19(5):445-453. PubMed ID: 37968978
[TBL] [Abstract][Full Text] [Related]
10. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
Vosburg SK; Haynes C; Besharat A; Green JL
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
[TBL] [Abstract][Full Text] [Related]
11. Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study.
Black JC; Margolin ZR; Olson RA; Dart RC
JMIR Public Health Surveill; 2020 Jun; 6(2):e17073. PubMed ID: 32597786
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV).
Vosburg SK; Beaumont J; Dailey-Govoni ST; Butler SF; Green JL
Pain Med; 2020 Sep; 21(9):1891-1901. PubMed ID: 31617931
[TBL] [Abstract][Full Text] [Related]
13. Web-Based Discussion and Illicit Street Sales of Tapentadol and Oxycodone in Australia: Epidemiological Surveillance Study.
Black J; Margolin ZR; Bau G; Olson R; Iwanicki JL; Dart RC
JMIR Public Health Surveill; 2021 Dec; 7(12):e29187. PubMed ID: 34932012
[TBL] [Abstract][Full Text] [Related]
14. Tapentadol abuse and dependence in India.
Mukherjee D; Shukla L; Saha P; Mahadevan J; Kandasamy A; Chand P; Benegal V; Murthy P
Asian J Psychiatr; 2020 Mar; 49():101978. PubMed ID: 32120298
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product: Results From 3 Postmarket Surveillance Studies.
Butler SF; McNaughton EC; Black RA; Cassidy TA
Clin J Pain; 2018 Jul; 34(7):618-628. PubMed ID: 29298186
[TBL] [Abstract][Full Text] [Related]
16. Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study.
Cepeda MS; Fife D; Vo L; Mastrogiovanni G; Yuan Y
J Pain; 2013 Feb; 14(2):158-64. PubMed ID: 23253635
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse.
Cepeda MS; Fife D; Kihm MA; Mastrogiovanni G; Yuan Y
Clin J Pain; 2014 Dec; 30(12):1051-6. PubMed ID: 24370606
[TBL] [Abstract][Full Text] [Related]
18. Is tapentadol a potential Trojan horse in the postdextropropoxyphene era in India?
Basu A; Mahadevan J; Ithal D; Selvaraj S; Chand PK; Murthy P
Indian J Pharmacol; 2018; 50(1):44-46. PubMed ID: 29861527
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
20. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
